Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of CDP870 in Active Crohn's Disease (Extension Study)
NCT00329420Phase 2Completed
- Sponsor
- UCB
- Start
- May 2006
- Primary completion
- May 2008
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of certolizumab pegol in Crohn's disease, sponsored by UCB. Started May 2006; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00329420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00329420.